Pharmacokinetics, Brain Delivery, and Efficacy in Brain Tumor-Bearing Mice of Glutathione Pegylated Liposomal Doxorubicin (2B3-101)

Pieter J. Gaillard, Olaf van Tellingen(Dutch Cancer Society), Daniëlle J. Vugts(Amsterdam University Medical Centers), David Maussang(Vrije Universiteit Amsterdam), Chantal C.M. Appeldoorn, Joan van Kregten, Rick Dorland, Francesca Manca, Helga E. de Vries(Amsterdam Neuroscience), Guus A.M.S. van Dongen(Amsterdam UMC Location Vrije Universiteit Amsterdam), Albert D. Windhorst(Amsterdam UMC Location Vrije Universiteit Amsterdam)
PLoS ONE
January 8, 2014
10.1371/journal.pone.0082331
Cited by 280

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
|PubMed|2002|688